Hormone Replacement Therapy in Cancer Survivors: A Con Opinion

Carolyn D. Runowicz, MD

Introduction

Successful treatment of patients with cancer has resulted in an ever-increasing population of cancer survivors. With their cancer treatments behind them, these survivors are now facing the challenges of living a normal life. Following cancer therapy, women may experience menopausal symptoms, such as hot flashes, dyspareunia, atrophic vaginitis, and sleep disturbances. Menopause may be prematurely precipitated by the therapy or may naturally occur. Coronary artery disease and osteoporosis are potentially life-threatening conditions associated with aging and menopause. As in the general population, cardiovascular disease is currently the most common nonneoplastic cause of death in breast cancer survivors. \(^1\) Estrogen replacement therapy has been shown to protect against heart disease and bone fractures. Thus, the issue of hormone replacement therapy in cancer survivors is a very real issue that needs to be addressed by practicing physicians. For women with breast cancer and uterine cancer, the issue of hormone replacement is quite complex with conflicting data and opinions.

Breast Cancer

Cellular Effects of Hormones

Available data are consistent with the idea that endocrine factors are involved in either the induction and/or promotion of breast cancer. Hormones act by increasing cell proliferation. Cellular DNA may be more susceptible to carcinogens during division. Mutations that occur spontaneously or from carcinogens are more likely to occur in rapidly dividing cells. Cell proliferation increases the risk of tumorigenesis by accelerating the accumulation of stochastic somatic genetic errors, including mutations, translocations, and reduction to homozygosity of tumor suppressor genes. \(^2\)

Estrogen stimulates growth of normal and malignant breast cells in tissue culture. \(^3\) Progesterone also has proliferative actions in the breast. In mice, progesterone stimulates DNA synthesis in the epithelium of the terminal bud and ductal epithelium. In epithelial cells of the breast during the normal menstrual cycle and in women taking oral contraceptives, the highest thymidine labeling indices occur during the progestin-dominated secretory phase of the menstrual cycle. \(^4\)

The epithelial cells of the terminal duct lobular units, from which the vast majority of breast cancers arise, undergo significant changes during the menstrual cycle. Cell proliferation of the terminal duct lobular units is increased during the secretory phase of the menstrual cycle. \(^5\)

Dr. Runowicz is Professor and Director of the Division of Gynecologic Oncology of the Department of Obstetrics and Gynecology at the Albert Einstein College of Medicine and Montefiore Medical Center in the Bronx, New York.
duct lobular units is lowest during the follicular phase, then increases some fourfold to peak in the mid to late luteal phase. However, some research suggests that progestins induce only one round of cell replication, after which cells differentiate and cease proliferating, as opposed to estrogen, which appears to induce multiple replications. The conflicting data in the literature with respect to progesterone may be a result of experimental conditions, dose of progesterone used, and the animal model studied. Local growth factors may be either stimulatory or inhibitory for cell growth depending on the relative concentrations of estrogen and progesterone.

Epidemiology

Role of Endogenous Hormones

Epidemiologic data support a role for hormones in the development of breast cancer. The incidence of breast, ovary, and endometrial cancer show a sharp slowing of the rate of rise of these cancers at the age of menopause (Figure). The simplest interpretation of this phenomenon is that the key etiologic elements are present in premenopausal women. Ovarian steroid hormones may be the key factors. Low serum levels of estrogens in women in China and Japan may partially explain the large differences in breast cancer risk between these Asian countries and the West.

Numerous reports have documented the protective effect of late menarche and early menopause on breast cancer risk. It is estimated that bilateral oophorectomy at 35 years of age is associated with a relative risk of .30 when compared with a natural menopause at age 50 (i.e., fifteen years of ovarian failure is associated with a 70 percent reduction in breast cancer risk). The Cancer and Steroid Hormone Study Group reported that hysterectomy with bilateral salpingo-oophorectomy decreases the risk of breast cancer in women younger than 55 years, possibly by curtailing ovarian function at a critical period. It has been argued that premenopausal women with breast cancer who maintain their ovarian function have a prognosis and survival equal to that of postmenopausal women and, thus, provide indirect evidence for the safety of hormonal therapy. Recent data from several large studies, however, question the validity of this logic. The Scottish Cancer Trial’s Breast Group and ICRF Breast Unit in London in a randomized, prospective trial with long-term follow-up demonstrated that oophorectomy in premenopausal women was as effective as standard chemotherapy. The Early Breast Cancer Trialists reported ovarian ablation in women younger than 50 was associated with a 26 percent reduction in recurrence and a 25 percent reduction in mortality. Similarly, Bianco et al found that those women who experience either temporary or permanent amenorrhea during chemotherapy for breast cancer had a significantly better survival.

Role of Exogenous Hormones

Since 1970, at least 39 epidemiologic studies have examined the association of exogenous estrogen treatment and risk of available data are consistent with the idea that endocrine factors are involved in either the induction and/or promotion of breast cancer.
breast cancer. The findings of these studies are not consistent. A recent analysis that pooled duration response slopes from 16 case-control studies reported a relative risk of 1.3 (95 percent confidence interval, 1.2-1.6) for women who had used estrogens more than 15 years, as compared with nonusers. Grady et al calculated a risk of breast cancer of 1.25 in women who used estrogen for more than eight years, from pooled estimates of case-control and cohort studies. However, the authors caution that this risk may be too high due to a surveillance bias for those women who took estrogen or too low if estrogen treatment had been withheld from women at high risk for breast cancer. Hemminki and Sihvo reviewed recommendations for postmenopausal hormone therapy. Their report suggests that until the 1990s, physicians in the United States tended to select healthier women for long-term estrogen therapy. Thus, exclusion from hormone therapy of women with an increased risk, history of, or current breast or gynecologic cancer from hormone therapy may have biased published surveys toward underestimating the real risk of breast cancer.

Further data implicating a role for estrogen in breast cancer were recently reported by Colditz et al in a meta-analysis of 31 studies. Current users of hormone replacement therapy had a significantly elevated relative risk of breast cancer as compared with never-users, with a 40 percent increased risk of breast cancer (relative risk, 1.40; 95 percent confidence interval, 1.2-1.63).

In the Nurses Health Study, these same authors observed that the risk of breast cancer was significantly elevated among current users (relative risk, 1.36; 95 percent confidence interval, 1.41-1.667). Similarly, Hunt et al observed an increased risk of breast cancer in current users of estrogen replacement therapy among women attending a menopause clinic in Great Britain. Mills et al found that current estrogen use was associated with a significant increase in breast cancer risk. These data taken together with other epidemiologic data and laboratory evidence suggest that estrogen is a promoter of mammary tumors. The widespread use of estrogen replacement therapy and hormone replacement therapy and the incidence of breast cancer combine to make even a small increase in relative risk (25 to 30 percent) an important public health issue.

More evidence implicating hormones in the pathogenesis of breast cancer is evident in studies evaluating diethylstilbestrol in the mothers who took this drug during pregnancy. There is an increased relative risk of breast cancer in the mothers of about 1.35. These data suggest a long latency effect. This phenomenon has also been observed in women who used the oral contraceptive pill. There is evidence of a modest increase in breast cancer risk in women diagnosed under the age of 45 years who took the birth control pill following menarche and in those who took the oral contraceptive pill for long periods of time prior to the first full-term pregnancy. These cancers did not become apparent until 10 to 20 years following cessation of the oral contraceptive pill.

Premenopausal women who are given tamoxifen may have increased levels of serum estradiol. Proponents for hormone replacement therapy argue that this has not appeared to affect their prognosis. However, the difficulty with this logic is that not all premenopausal patients demonstrate an increase in serum estradiol, and sufficiently large numbers

---

**Epidemiologic data support a role for hormones in the development of breast cancer.**

---

Vol. 46 No. 6 November/December 1996 367
of premenopausal patients have not received long-term tamoxifen to justify a secure position of no effect on prognosis. It also appears that there is an increase in steroid hormone binding globulin, and thus the estradiol may be bound and not free.

Proponents of estrogen replacement therapy for breast cancer survivors bolster their arguments by stating that estrogen has been and is currently used as a treatment for breast cancer. However, the dose is pharmacologic, not physiologic, and in-vitro studies demonstrate that low doses of estrogens can stimulate, while high doses of estrogen inhibit breast cancer growth.

**GENETICS**

A personal history of breast cancer is a strong risk factor for the subsequent development of another primary breast tumor. The annual incidence of new primary breast cancers among breast cancer survivors is 14 per 1,000 women compared with an incidence of two per 1,000 women in the general population. The risk of breast cancer is also increased in women with cancers of the corpus uteri and ovary, with a relative risk of about 1.5 from one to four years after the diagnosis of the first cancer. Follow-up surveys of patients with ovarian cancer reveal an increased risk of second primary cancers of the uterine corpus, colon, bladder, breast, and hematopoietic system.

**PREGNANCY**

Proponents of hormone replacement therapy argue that if pregnancy is safe following breast cancer, then hormone replacement therapy should also be safe. However, this intuitive logic is too simplistic. The levels of hormones in pregnancy cannot be compared with levels achieved with hormone replacement therapy. In addition to estrogen and progesterone, corticosteroid, growth hormone, insulin, and prolactin are increased in pregnancy. The interaction of these hormones and the elevated levels do not provide an analogous situation to hormone replacement therapy.

Animal and laboratory data suggest that pharmacologic doses of estrogen and progesterone can inhibit the growth of breast cancer. At high doses, progesterone appears to be antiproliferative in breast cancers. The estrogen and progesterone levels observed in pregnancy cause cells to differentiate and the breast tissue in animals becomes more resistant to the stimulatory effects of estrogen. The mammary gland of different species responds differently to estrogens, depending on the dose and whether it is administered alone or in combination with progesterone.

Recent data suggest that concurrent or recent pregnancy adversely affects survival of young women (aged 20 to 29 years) with breast cancer. Adjustment for number of axillary nodes and stage of dis-
ease reduced the relative risk only slightly (relative risk, 2.83; 95 percent confidence interval, 1.24-6.45, \( P=0.023 \)). Another study observed a dual effect of pregnancy on the risk of breast cancer. There was a transient increase in breast cancer following childbirth, but a reduction in later years. These authors suggest that pregnancy results in an initial increase in risk by stimulating the growth of cells that have undergone the early stages of malignant transformation and results in long-term protection by inducing the differentiation of normal mammary stem cells that have the potential for neoplastic change.

There have been several reports (which together total about 500 patients) following patients who have had pregnancies following breast cancer. This information is of importance to patients with breast cancer who wish to address this issue. Although the reported cases do not seem to contraindicate pregnancy following breast cancer, this data must be viewed with caution. The reported series are small, and represent a naturally selected group of survivors. Most reports have an interval of several years from the time of breast cancer to the time of conception. More worrisome is that most reports do not have adequate follow-up and report median follow-up periods of only two to three years. A significant percentage of patients who undergo treatment of breast cancer have occult metastasis, and even those with small tumors and negative nodes have a ten-year survival rate of 70 percent. Recurrence rates of five percent per year have been reported for up to ten years. The actual annual risk is relatively linear over the first ten to twelve years after therapy. Few of the published studies have a follow-up of ten years.

**Methodologic Limitations of Human Studies of Hormone Replacement Therapy in Breast Cancer Survivors**

There have been several small studies that have reported estrogen replacement therapy or estrogen and progesterone replacement therapy in patients with breast cancer. The published trials to date have been anecdotal and not formal clinical trials with clearly defined objectives, eligibility criteria, and end points. Stoll administered daily doses of 0.625 milligrams of conjugated equine estrogens and 0.15 milligram norgestrel to symptomatic postmenopausal woman with a history of breast cancer, but clinically free of recurrence. Treatment was given continuously for three months and if symptoms improved was continued for an additional three months. The patients were followed for at least two years. The authors did not report any tumor reactivation during that period of observation. This clinical trial is difficult to analyze as it is reported in summary form, without a clear definition of the patient population. The treatment interval and follow-up period was too short to provide reassuring data that hormone replacement is safe to administer.

Wile et al conducted a case-control study of 25 breast cancer survivors who received estrogen replacement therapy. The mean duration of treatment was 35.2 years.
months, with a range of six to 78 months. The study is a small, retrospective study with different regimens of hormone replacement therapy and different doses. The authors conclude that the study does not have the power to demonstrate an adverse affect of hormone replacement therapy on breast cancer.

The American College of Obstetricians and Gynecologists in their Committee Opinion in April 1994 reevaluated the use of estrogen replacement therapy in women with previously treated breast cancer. In this Committee Opinion, they conclude that in postmenopausal women with previously treated breast cancer, consideration of estrogen replacement therapy is an option but must be viewed with caution. The opinion further states that any possible benefit must be balanced by a thorough explanation of current knowledge, which by necessity will entail consultation with the patient’s oncologist. The American College of Physicians in their guidelines for hormone replacement therapy concluded the risks of hormone therapy may outweigh its benefits in women who are at increased risk for breast cancer.

**Endometrial Cancer**

**Role of Exogenous Hormones**

Women with a uterus receiving estrogen therapy have about a 20 percent lifetime probability of having a hysterectomy because of endometrial hyperplasia or cancer due to the therapy. There does not seem to be an increased risk when the estrogen is combined with progesterone therapy. The lifetime risk for developing endometrial cancer is increased about eightfold in women with a uterus who take unopposed estrogen for 10 to 20 years. Long-term estrogen replacement therapy is associated with an increased risk of developing endometrial cancer, which persists for up to 10 years following cessation of estrogen therapy, again suggesting a long latency effect.

**Methodologic Limitations of Human Studies**

There have been several retrospective, nonrandomized studies of patients given estrogen replacement therapy following treatment for endometrial cancer. Creasman et al reported 47 patients who were treated with estrogen replacement therapy after therapy for endometrial cancer. The patients were treated with a variety of estrogens including both oral and vaginal preparations. Estrogen therapy was given after a median interval from cancer therapy of 15 months. Thus, the study represents a selection bias, suggesting that the authors may have eliminated patients who developed recurrent disease in the initial 15 months following therapy. The groups were not evenly matched, and the patient numbers were too small to achieve a statistically significant difference. The authors do note a trend for several factors pointing to a more favorable disease status in the estrogen group. With larger numbers, this trend would have probably been of statistical significance.

Lee et al reported on 44 patients placed on estrogen replacement therapy following treatment for endometrial cancer. The patients were at low risk for recurrence due to strict selection criteria that included well differentiated tumors, superficial invasion, and no evidence of metastatic disease. Treatment was started within the first year following therapy in 57 percent of the patients. The dose of
conjugated estrogen therapy ranged from 0.625 to 1.25 for 25 days each month and 15 patients also took proges- terone (34 percent). This study suffers from the same deficiencies as the Creas man report.

In a letter to the editor, Bryant\textsuperscript{34} reported treating 20 patients with oral estrogen after treatment for endometrial cancer, beginning 18 to 24 months after surgery using daily doses of 0.625 mg conjugated estrogens. Nine patients received medroxyprogesterone acetate suspension (DepoProvera) prior to starting estrogen therapy. No mean or medium follow-up is given. Because these data are presented only as correspondence to the editor, it cannot be given credence beyond that of an anecdote.

In a review article, Baker\textsuperscript{35} reported a small series of 31 patients who received estrogen replacement therapy between 1972 and 1988. The patients received a variety of oral, oral and vaginal, or transdermal estrogen therapy. The strict selection criteria resulted in a group that was at a very low risk of recurrence. This preliminary data is presented in a summarized format.

A survey of members of the Society of Gynecologic Oncologists indicated that 83 percent of respondents approved of estrogen replacement therapy in stage I, grade 1 tumors; 56 percent favored using estrogen in the case of stage I, grade 2 tumors; and only 39 percent favored using estrogen in patients with stage I, grade 3 tumors. This survey has been used as a rationale for the safety of estrogen replacement therapy. However, it should be remembered that a survey is not a peer-reviewed mechanism of evaluating a treatment, and there is also the issue of nonrespondents, which can substantially bias a survey outcome.

In a Committee Opinion in August 1993, The American College of Obstetricians and Gynecologists concluded that there are no definitive data to support specific recommendations regarding the use of estrogen in women previously treated for endometrial carcinoma. The opinion states that estrogens could be used for the same indications as for any other woman, except that the selection of appropriate candidates should be based on prognostic indicators and the risk the patient is willing to assume. The need for progesterational agents in addition to estrogens could not be evaluated by the Gynecologic Practice Committee due to the paucity of data.\textsuperscript{36}

**Summary**

In patients with hormonally sensitive tumors, estrogen replacement therapy carries a theoretical risk of stimulating recurrent disease as well as contributing to an increased risk of other hormonally related cancers. In women with hormone-related cancers, it is unknown if their inherently increased risk for other related cancers can be further increased by the administration of hormones. In genetically susceptible animal models, hormones have been shown to promote growth of hormonally sensitive cancers. The uncertainty and potential risk of hormone replacement therapy demonstrates the need for randomized, prospective trials to provide women with a reasonable basis for therapeutic alternatives. The most prudent approach with this population is to consider alternative treatments until the ongoing, randomized clinical trials

*Long-term estrogen replacement therapy is associated with an increased risk of developing endometrial cancer.*
have been evaluated with adequate long-term follow-up. Until such time, nonhormonal alternatives to manage symptomatic patients should be employed. It is incumbent on physicians to educate themselves and become adept in their use. Diet and exercise will have to be an essential component of the counseling provided to patients following cancer therapy.

References

1. Rosen PP, Groshen S, Kinne DW, Norton L: Factors influencing prognosis in node-negative breast carcinoma: Analysis of 767 T1NOMO/T2NOMO patients with long-term follow-up. J Clin Oncol 1993;11:2090-2100.
2. Spicer DV, Pike MC: The prevention of breast cancer through reduced ovarian steroid exposure. Acta Oncol 1992;31:167-174.
3. Thomas DB, Persing JP, Hutchinson WB: Exogenous estrogens and other risk factors for breast cancer in women with benign breast diseases. J Natl Cancer Inst 1982;69:1017-1025.
4. Horwitz KB: The molecular biology of RU486: Is there a role for antiprogestins in the treatment of breast cancer. Endocr Rev 1992;13:146-163.
5. Staffa JA, Newschaffer CJ, Jones JK, Miller V: Progestins and breast cancer: an epidemiologic review. Fertil Steril 1992;57:473-491.
6. Irwin KL, Lee NC, Peterson HB, et al: Hysterectomy, tubal sterilization, and the risk of breast cancer. Am J Epidemiol 1988;127:1192-1201.
7. Kelsey JL: Breast cancer epidemiology: Summary and future directions. Epidemiol Rev 1993;15:256-263.
8. Scottish Cancer Trials Breast Group and ICRF Breast Unit, Guy's Hospital, London: Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: The Scottish Trial. Lancet 1993;341:1293-1297.
9. Early Breast Cancer Trialists Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992;339:71-85.
10. Bianco AR, Del Mastro L, Gallo C, et al: Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer. Br J Cancer 1991;63:799-803.
11. Steinberg KK, Thacker SB, Smith SJ, et al: A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1994;271:1885-1890.
12. Grady D, ERNERT V: Invited commentary: Does postmenopausal hormone therapy cause breast cancer? Am J Epidemiol 1991;134:1396-1400.
13. Hemminki E, Silivo S: A review of postmenopausal hormone therapy recommendations: Potential for selection bias. Obstet Gynecol 1993;82:1021-1028.
14. Colditz GA, Egan KM, Stampfer MJ: Hormone replacement therapy and risk of breast cancer: Results from epidemiologic studies. Am J Obstet Gynecol 1993;168:1473-1480.
15. Colditz GA, Stampfer MJ, Willett WC, et al: Prospective study of estrogen replacement therapy and risk of breast cancer in postmenopausal women. JAMA 1990;264:2648-2653.
16. Hunt K, Vessey M, McPherson K, Coleman M: Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynecol 1987;94:620-635.
17. Mills PK, Beeson WL, Phillips RL, Fraser GE: Prospective study of exogenous hormone use and breast cancer in Seventh-Day Adventists. Cancer 1989;64:591-597.
18. Colton T, Greenberg ER, Noller K, et al: Breast cancer in mothers prescribed diethylstilbestrol in pregnancy: Further follow-up. JAMA 1993;269:2096-2100.
19. White E, Malone KE, Weiss NS, Daling JR: Breast cancer among young U.S. women in relation to oral contraceptive use. J Natl Cancer Inst 1994;86:505-514.
20. Eden JA: Oestrogen and the breast: 1. Myths about estrogen and breast cancer. Med J Aust 1992;157:175-177.
21. Lippman M, Bolan G, Huff K: The effects of estrogen and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res 1976;36:4595-4601.
22. Ewertz M, Storm HH: Multiple primary cancers of the breast, endometrium and ovary. Eur J Cancer Clin Oncol 1989;25:1927-1932.
23. Reimer RR, Hoover R, Fraumeni JF Jr, Young RC: Second primary neoplasms following ovarian cancer. J Natl Cancer Inst 1978;61:1195-1197.
24. Mauvais-Jarvis P, Kuttenn F, Gompel A: Antiestrogen action of progesterone in breast tissue. Breast Cancer Res Treat 1986;8:179-187.
25. Guinee VF, Olsson H, Moller T, et al: Effect of pregnancy on prognosis for young women with breast cancer. Lancet 1994;343:1587-1589.
26. Lambe M, Hsieh C, Trichopoulos D, et al: Transient increase in the risk of breast cancer after giving birth. N Engl J Med 1994;331:5-9.
27. Stoll BA: Hormone replacement therapy in women treated for breast cancer. Eur J Cancer Clin Oncol 1989;25:1909-1913.
28. Wile AG, Opfell RW, Margileth DA: Hormone replacement therapy in previously treated breast cancer patients. Am J Surg 1993;165:372-375.
29. American College of Obstetrics and Gynecology: Committee opinion: Estrogen replacement therapy in women with previously treated breast cancer. Number 1994;135:1-4.
30. American College of Physicians: Guidelines for counseling postmenopausal women about preventive hormone therapy. Ann Intern Med 1992;117:1038-1041.
31. Hulka B: Effect of exogenous estrogen on postmenopausal women: The epidemiologic evidence. Obstet Gynecol Surv 1980;35:389-399.
32. Creasman WT, Henderson D, Hinshaw W, Clarke-Pearson DL: Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol 1986;67:326-330.
33. Lee RB, Burke TW, Park RC: Estrogen replacement therapy following treatment for Stage I endometrial carcinoma. Gynecol Oncol 1990;36:189-191.
34. Bryant GW: Administration of estrogens to patients with a previous diagnosis of endometrial adenocarcinoma (letter). South Med J 1990;83:725-726.
35. Baker DP: Estrogen-replacement therapy in patients with previous endometrial carcinoma. Compr Ther 1990;16:28-35.
36. American College of Obstetricians and Gynecologists: Committee Opinion. Estrogen replacement therapy and endometrial cancer. Number 126, 1993.

**UICC First International Meeting on Advances in the Knowledge of Cancer Management**

**Vienna, Austria**  
**June 21 to July 1, 1997**

The International Union Against Cancer is organizing its first Cancer Management Meeting in Vienna from June 29 to July 1, 1997. The meeting will deal predominantly with selected topics where new knowledge has been acquired or progress made in understanding the molecular biology and/or treatment of the disease.

The program will offer important new information for clinicians and scientist working in oncology as well as for oncology nurses. It will provide an opportunity for direct interaction and exchange of ideas with lecturers of diverse professional backgrounds and for participation in workshops concentrating on breast, prostate, and colorectal cancers organized in parallel with the meeting.

For further information, contact Mr. A.J. Turnbull, UICC, 3 rue de Conseil-General, CH-1205 Geneva, Switzerland; telephone: (+41/22) 809 18 11; fax:(+41/22) 809 18 10 or Univ.-Prof. Dr. H. Ludwig, 1st Department of Medicine and Medical Oncology, Wilhelminenspital, Montleartstrasse 37, A-1171 Vienna, Austria; telephone: (+43/1) 49150-2711; fax: (+43/1) 49150-2554.